GEMMABio Unveils Duchenne Muscular Dystrophy (DMD) Program and Presents Preclinical Data for Next‑Generation Gene Therapies for DMD and Spinal Muscular Atrophy Type 1 (SMA1 ...

Gemma Biotherapeutics ("GEMMABio"), a clinical‑stage, global, genetic medicines company, today announced the presentation of preclinical data supporting candidate declaration for GB703, a novel, ...

Precision BioSciences Presents New Preclinical Data Supporting the Advancement of PBGENE-DMD into Clinic at the American Society of Gene & Cell Therapy 2026 Annual Meeting

Precision BioSciences, Inc. (Nasdaq: DTIL), a clinical stage gene editing company utilizing its novel proprietary ARCUS® platform to develop in vivo gene editing therapies for high unmet need diseases ...
AOL

US FDA to convene expert panel for Capricor Therapeutics' DMD cell therapy

(Reuters) -Capricor Therapeutics said on Monday the U.S. Food and Drug Administration (FDA) plans to convene a panel of outside experts before deciding on the company's cell therapy for a heart ...
GlobalData on MSN

REGENXBIO to push for accelerated approval of DMD gene therapy

REGENXBIO touted data from the Phase III portion of a study that showed higher benefit that Elevidys.
The American Journal of Managed Care

DMD Gene Therapy Shows Clinical Benefits in 8- and 9-Year-Old Patients

Delandistrogene moxeparvovec-rokl shows significant motor function improvements in 8- and 9-year-olds with DMD, countering expected motor decline. Statistically significant differences were observed ...
Business Wire

Precision BioSciences Accelerates Development of PBGENE-DMD Within its Wholly Owned Organic Pipeline and Highlights Pre-clinical Evidence at the American Society of Gene and ...

DURHAM, N.C.--(BUSINESS WIRE)--Precision BioSciences, Inc. (Nasdaq: DTIL), a clinical stage gene editing company utilizing its novel proprietary ARCUS® platform to develop in vivo gene editing ...
MedPage Today on MSN

Cell therapy slows upper limb decline in Duchenne muscular dystrophy

Investigational deramiocel is back under FDA review again ...
pharmaphorum

Capricor sues partner Nippon Shinyaku in DMD therapy spat

Capricor Therapeutics has fallen out with its commercial partner for Duchenne muscular dystrophy (DMD) cell therapy ...
Medical Xpress

Cell therapy prevents damage from Duchenne muscular dystrophy in mouse model

A cell therapy preserves muscle structure and function in laboratory mice with a type of disease similar to Duchenne muscular dystrophy, according to new research from the Smidt Heart Institute at ...
Stocktwits on MSN

CAPR stock sinks after-hours: Capricor launches legal fight over DMD therapy rollout ahead of FDA review

Capricor alleged that NS Pharma failed to prepare for Deramiocel’s commercial rollout and refused to fix pricing flaws in the commercialization agreement. ・The company claims that the current pricing ...
Medical News Today

Duchenne muscular dystrophy (DMD) treatment options

Duchenne muscular dystrophy (DMD) causes muscle weakness that becomes more severe over time. While there is no cure, treatments can help slow the progression and manage symptoms and complications.
Healthline

Duchenne Muscular Dystrophy (DMD) Treatment Options

There is no cure for DMD, but treatments can slow the progression of the disease and help improve quality of life. Duchenne muscular dystrophy (DMD) is a chronic condition that causes a gradual loss ...